Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Prostate Clear all

Conditions: Prostate Cancer
Interventions: Radiation Therapy; Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Sacramento, California • Ann Arbor, Michigan

Conditions: Prostate Cancer
Interventions: Prohibitin-TP01; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostatic Neoplasms
Interventions: Cabozantinib, Docetaxel, Prednisone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: iRAI; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Prostate Cancer
Interventions: Focal prostate brachytherapy with Cesium-131; Radiation
Lead sponsor: Ronald M. Benoit, MD; Other
Eligibility: Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer
Interventions: 1.5 T Elekta Unity MR-Linac system, Hydrogel rectal spacer (SpaceOAR); Radiation · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: BN83495 (Cohort 1), BN83495 (Cohort 2), BN83495 (Cohort 3); Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Baltimore, Maryland • Durham, North Carolina • Madison, Wisconsin

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: ZEN003694, Enzalutamide; Drug
Lead sponsor: Zenith Epigenetics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Whittier, California + 13 more

Conditions: Prostate Cancer
Interventions: soy protein isolate, placebo; Dietary Supplement · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Adenocarcinoma of the Prostate
Interventions: STA9090, STA9090 with Dutasteride; Drug
Lead sponsor: Toni Choueiri, MD; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Recurrent Prostate Cancer After Surgery
Interventions: Daily-adaptive Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Prostate Cancer
Interventions: Proton Radiation, Proton; Radiation
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Oscar Goodman, Jr.; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Prostatic Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: New Orleans, Louisiana • Omaha, Nebraska • Syracuse, New York

Conditions: Prostate Adenocarcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Prostate, Cancer
Interventions: QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostatic Neoplasms, Castration-Resistant
Interventions: BI 836845, Enzalutamide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 3
States / cities: Detroit, Michigan • New York, New York • Portland, Oregon

Conditions: Neuroendocrine Prostate Cancer
Interventions: Tarlatamab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Phoenix, Arizona • San Francisco, California • Atlanta, Georgia + 7 more

Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Enzalutamide, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Magnetic Resonance Imaging, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
Interventions: Ga-68 PSMA-HBED-CC PET; Drug
Lead sponsor: Michael Graham PhD, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Prostate Cancer
Interventions: Tetrathiomolybdate; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Fluorine F 18 Sodium Fluoride; Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 4
States / cities: Boston, Massachusetts • Durham, North Carolina • Portland, Oregon + 1 more

Conditions: Prostate Cancer
Interventions: Starting the Conversation (STC), Time and Attention; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Hypofractionated Stereotactic Body Radiation Therapy (SBRT)

A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

UFPTI 2403-PR12: Real-Time Volumetric Ionizing Radiation Acoustic Imaging for In-vivo Proton Treatment Monitoring in Pencil-Beam Scanning

Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer

Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy

A Study of Telemedicine Shared Medical Appointments (SMAs) Versus Individual Telemedicine Visits for People With Prostate Cancer

BN83495 in Prostate Cancer

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer

STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling

This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.

Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer

Cultured Circulating Tumor Cells in Prostate and Other Cancers

Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases

Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)

Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer

Tetrathiomolybdate in Hormone Refractory Prostate Cancer

Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

Sexual Health Communication Skills Training Intervention for Patients With Prostate Cancer